Welcome to our dedicated page for Guardant Health SEC filings (Ticker: GH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Guardant Health's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Guardant Health's regulatory disclosures and financial reporting.
Guardant Health director Manuel Hidalgo Medina reported acquiring shares through equity awards. On the vesting of a restricted stock unit grant on July 17, 2024, 232 restricted stock units converted into 232 shares of common stock at a price of $0.00 per share, reflecting an exercise or conversion of a derivative security rather than an open-market purchase. After these transactions, he directly holds 6,729 restricted stock units and 1,493 shares of common stock. The award vests over four years, with 25% vesting on the one-year anniversary of July 17, 2024 and the remaining 75% vesting monthly over the following three years.
Guardant Health director Tariq Musa reported a routine equity compensation transaction. On February 15, 2026, he exercised or converted 250 Restricted Stock Units at $0 into 250 shares of Guardant Health common stock.
Following this derivative conversion, Musa directly holds 8,493 shares of common stock and 3,248 Restricted Stock Units. The RSUs were part of an award granted on March 6, 2023 that vests over four years, with 25% vesting after the first year and the remaining 75% vesting monthly over the next three years.
Guardant Health director Steve Krognes reported a routine equity compensation event. On January 31, 2026, 154 Restricted Stock Units vested at an exercise price of $0, resulting in the acquisition of 154 shares of common stock. Following this transaction, he directly holds 18,899 shares of common stock and 772 Restricted Stock Units.
The vested RSUs come from an award granted on August 9, 2022, which vested 25% of the shares on June 30, 2023. The remaining 75% vests in substantially equal monthly installments over the three years after June 30, 2023.
Guardant Health Chief People Officer Terilyn J. Monroe reported multiple open-market sales of company stock. On January 21, 2026, she sold 1,703 shares of Guardant Health common stock at a weighted average price of $112.3418 per share, 3,619 shares at a weighted average price of $113.4793 per share, and 3,249 shares at a weighted average price of $115.6978 per share. Each sale was executed in multiple transactions within disclosed price ranges. After these sales, Monroe directly beneficially owned 20,990 shares of Guardant Health common stock.
Guardant Health director Roberto Mignone reported a routine vesting of equity awards. On 01/21/2026, 264 Restricted Stock Units converted into 264 shares of Guardant Health common stock at an exercise price of $0 per share, increasing his directly held common stock to 3,959 shares. The related RSU award, granted on November 8, 2024, vests over four years: 25% of the shares vested on the one-year anniversary of 10/21/2024, and the remaining 75% vests in equal monthly installments over the following three years. After this vesting event, Mignone directly holds 8,712 RSUs in addition to his common shares.
Guardant Health, Inc. (GH) insider Terilyn J. Monroe has filed a Form 144 indicating an intent to sell additional shares of company stock. The filing covers 8,571 shares of common stock to be sold through Charles Schwab & Co., Inc. on or about 01/21/2026 on the NASDAQ, with an aggregate market value of 977902.00. These shares were acquired on 01/15/2026 via a restricted stock lapse as equity compensation from Guardant Health, Inc.
The filing also lists prior sales over the past three months. Monroe sold 55,167 shares of Guardant Health, Inc. on 12/01/2025 for gross proceeds of 5846164.00, and 10,031 shares on 01/07/2026 for gross proceeds of 1124200.00. Guardant Health, Inc. had 126,041,089 shares of common stock outstanding, providing context for the size of these transactions relative to the total share base.
Guardant Health director Manuel Hidalgo Medina reported a routine equity award vesting. On January 17, 2026, 232 Restricted Stock Units converted at an exercise price of $0 into 232 shares of common stock. After this transaction, he beneficially owned 1,261 shares of common stock directly and 6,961 Restricted Stock Units.
The Restricted Stock Units were granted on July 17, 2024 and vest over four years. 25% of the award vested on the one-year anniversary of that grant date, and the remaining 75% vests in equal monthly installments over the following three years.
Guardant Health director Musa Tariq reported the vesting and conversion of 250 restricted stock units into 250 shares of common stock at a price of $0 per share on January 15, 2026. Following this transaction, he directly owns 8,243 shares of Guardant Health common stock and 3,498 restricted stock units. The RSUs were granted on March 6, 2023 and vest over four years: 25% of the award vested on the one-year anniversary of March 15, 2023, with the remaining 75% vesting monthly over the subsequent three-year period.
Guardant Health reported that Chief People Officer Terilyn J. Monroe had 17,379 Restricted Stock Units settle into 17,379 shares of Common Stock on January 15, 2026. Of these, 8,808 shares were retained by the company at $111.98 per share to satisfy tax withholding obligations, and she now holds 29,561 shares of Common Stock directly. The underlying RSU award was granted on February 26, 2024 and vests 33% on the one-year anniversary of January 15, 2024, with the remaining 67% vesting annually over the following two-year period.
Guardant Health, Inc. reported that on January 11, 2026 it announced certain preliminary unaudited financial information for the quarter and full year ended December 31, 2025. This information is provided in a press release that is furnished as Exhibit 99.1 to the report, rather than being formally filed, which limits how it is incorporated into other regulatory documents.
The company also disclosed that it will post the investor presentation used at the 2026 J.P. Morgan Healthcare Conference, scheduled for January 12, 2026, on its website under the Investors section. These updates are intended to give the market an early view of recent performance and the materials being shared with investors.